SEC Form 4 · accession 0001144204-16-127098
INTERCEPT PHARMACEUTICALS, INC. · ICPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Shapiro
Officer — CMO and EVP - Development
Period of report
Oct 3, 2016
Accepted (ET)
Oct 5, 2016 · 9:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001270073
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 3, 2016 | M | 1,350 | $21.50 | A | 46,196 | D | |
| Common Stock | Oct 3, 2016 | S | 1,350 | $163.06 | D | 44,846 | D | |
| Common Stock | Oct 3, 2016 | S | 163 | $163.1997 | D | 44,683 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF2 | $21.50 | Oct 3, 2016 | M | 1,350 | D | — | Nov 16, 2022 | Common Stock | 1,350 | 8,486 | D |
Explanation of responses
- F1The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person.
- F2All shares underlying this option have vested.
- F3Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee.